National Commission on the COVID–19 Pandemic Act
By Reps. Speier and Burgess

Companion legislation introduced by Senators Feinstein, Gillibrand, and Marshall

**Purpose:** To establish the ‘National Commission on the COVID–19 Pandemic’ in order to better understand and manage the increasing likelihood of pandemic threats and related health issues that the United States could face in the future.

**Summary:** Establishes the ‘Commission’ to conduct an investigation on the COVID-19 outbreak and identify lessons learned regarding preparedness, response, and recovery.

The investigation shall address:

(A) U.S. government response efforts,
(B) public health messaging,
(C) international cooperation in responding to and investigating COVID-19,
(D) the availability of medical supplies and personal protective equipment,
(E) the development and distribution of treatments and vaccines,
(F) capacity of the U.S. health care system,
(G) language variations regarding novel diseases and how that relates to stigma/discrimination for certain communities,
(H) the origins of COVID-19, and
(I) any other subject the Commission determines relevant in developing recommendations to prepare for future pandemics.

**Composition:** The Commission shall be composed of 10 members (5 members appointed by each party).

**Reporting:** The Commission shall submit to the President and Congress, and make publicly available, an interim report not later than 1 year after the date of the bill’s enactment and a final report not later than 20 months after the initial meeting of the Commission.

**Powers:** The Commission has authority to hold hearings, take testimony, administer oaths, and issue subpoenas.

**Declassification of Evidence:** This bill also commences a declassification review of information the Commission requires relating to the origin of COVID–19.